non-small-cell lung cancer
FDA Criticizes Bristol Myers Squibb for Misleading Efficacy Claims on Krazati Website
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment
Actionable Insights Powered by AI
Bristol Myers Squibb, FDA, Krazati, misleading efficacy claims, non-small-cell lung cancer, NSCLC, KRAS G12C-mutated, cancer treatment